Peroxiredoxin 2: A potential biomarker for early diagnosis of Hepatitis B Virus related liver fibrosis identified by proteomic analysis of the plasma

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Lu, Ye ^a,b   Liu, Jie ^a   Lin, Chengzhao ^a   Wang, Haijian ^a   Jiang, Ying ^c   Wang, Jiyao ^a   Yang, Pengyuan ^a   He, Fuchu ^a,c  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; ALPHA2 GLYCOPROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; CD5 ANTIGEN; CLUSTERIN; COLLAGEN; FIBRINOGEN; HAPTOGLOBIN; HEMOPEXIN; LEUCINE RICH ALPHA2 GLYCOPROTEIN; MACROGLOBULIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PREALBUMIN; THIOREDOXIN PEROXIDASE; TRANSFERRIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; PEROXIREDOXIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DECISION TREE; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREDICTION; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; MASS SPECTROMETRY; METHODOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; BIOLOGICAL MARKERS; BLOTTING, WESTERN; EARLY DIAGNOSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PEROXIREDOXINS; PROGNOSIS; PROTEOMICS; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 77957725789     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-115     Document Type: Article

References (43)

1. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, Gallois Y, Rifflet H, Maiga MY, Penneau-Fontbonne D, Cales P. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997, 113:1609-1616. 10.1053/gast.1997.v113.pm9352863, 9352863.
2. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS-F. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526. 10.1053/jhep.2003.50346, 12883497.
3. Guéchot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III amino terminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994, 20:388-393. 10.1016/S0168-8278(94)80013-8, 8014451.
4. dos Santos VN, Leite-Mór MMB, Kondo M, Martins JR, Nader H, Lanzoni VP, Parise ER. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005, 38:747-753.
5. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino- terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996, 42:558-563.
6. El-Gindy I, El Rahman AT, El-Alim MA, Zaki SS. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease. Egypt J Immunol 2003, 10:27-35.
7. Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Transforming growth factor-β1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol 2005, 11:1929-1936.
8. Kim J, Kim SH, Lee SU, Ha GH, Kang DG, Ha NY, Ahn JS, Cho HY, Kang SJ, Lee YJ, Hong SC, Ha WS, Bae JM, Lee CW, Kim JW. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrixassisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis 2002, 23:4142-4156. 10.1002/elps.200290032, 12481271.
9. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Proteomic Analysis of Lung Adenocarcinoma: Identification of a Highly Expressed Set of Proteins in Tumors. Clin Cancer Res 2002, 8:2298-2305.
10. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002, 50:54-63. 10.1002/pros.10032, 11757036.
11. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF, Zhao YM, Steeg PS. Proteomics of Human Breast Ductal Carcinoma in Situ. Cancer Res 2002, 62:6740-6749.
12. Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal H, Pummer K, Adolf GR. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001, 1:890-898. 10.1002/1615-9861(200107)1:7<890::AID-PROT890>3.0.CO;2-Z, 11503213.
13. He QY, Chen J, Kung HF, Yuen APW, Chiu JF. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004, 4:271-278. 10.1002/pmic.200300550, 14730689.
14. Chen J, He QY, Yuen AP, Chiu JF. Proteomics of buccal squamous cell carcinoma: The involvement of multiple pathways in tumorigenesis. Proteomics 2004, 4:2465-2475. 10.1002/pmic.200300762, 15274141.
15. Zhang LY, Ying WT, Mao TS, He HZ, Liu Y, Wang HX, Liu F, Wang K, Zhang DC, Wang Y, Wu M, Qian XH, Zhao XH. Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003, 4:650-654.
16. Moreira JM, Gromov P, Celis JE. Expression of the tumor suppressor protein 14-3-3σ is down regulated in invasive transitional cell carcinoma of the urinary bladder undergoing epithelial mesenchymal transition. Mol Cell Proteomics 2004, 3:410-419. 10.1074/mcp.M300134-MCP200, 14736829.
17. Srisomsap C, Sawangareetrakul P, Subhasitanont P, Panichakul T, Keeratichamroen S, Lirdprapamongkol K, Chokchaichamnankit D, Sirisinha S, Svasti J. Proteomic analysis of cholangiocarcinoma cell line. Proteomics 2004, 4:1135-1144. 10.1002/pmic.200300651, 15048994.
18. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975, 250:4007-4021. 2874754, 236308.
19. Unlu M, Morgan ME, Minden JS. Two-Dimensional Electrophoresis Difference gel electrophoresis. A single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-2077. 10.1002/elps.1150181133, 9420172.
20. Wayne FP. Detection technologies in proteome analysis. J of Chromatography B 2002, 771:3-31.
21. Willard MF, Scott EH. Proteomics for protein expression profiling in neuroscience. Neurochemical Research 2004, 29:1065-1081. 10.1023/B:NERE.0000023594.21352.17, 15176464.
22. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer P. Classification of Chronic Hepatitis: Diagnosis, Grading and Staging. J Hepatology 1994, 19:1513-1520.
23. Lv S, Wei L, Wang JH, Wang JY, Liu F. Identification of Novel Molecular Candidates for Acute Liver Failure in Plasma of BALB/c Murine Model. J Proteome Res 2007, 6(7):2746-2752. 10.1021/pr0701759, 17569552.
24. Anderson NL, Anderson NG. The Human Plasma Proteome: History, Character, and Diagnostic Prospects. Mol Cell Proteomics 2002, 1:845-867. 10.1074/mcp.R200007-MCP200, 12488461.
25. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte Fatty Acid-Binding Protein Is a Plasma Biomarker Closely Associated with Obesity and Metabolic Syndrome. Clin Chem 2006, 52(3):405-413. 10.1373/clinchem.2005.062463, 16423904.
26. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer. Clin Cancer Res 2004, 10(10):3474-3478. 10.1158/1078-0432.CCR-03-0365, 15161704.
27. Putnam RW. the Plasma Proteins. 1975, 23-34. Academic Press, New York.
28. Tang HY, Ali-Khan N, Echan LA, Levenkova N, Rux JJ, Speicher DW. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 2005, 5:3329-3342. 10.1002/pmic.200401275, 16052622.
29. Echan LA, Tang HY, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 2005, 5:3292-3303. 10.1002/pmic.200401228, 16052620.
30. Kendziorski C, Irizarry RA, Chen KS, Haag JD, Gould MN. On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci USA 2005, 102:4252-4257. 10.1073/pnas.0500607102, 552978, 15755808.
31. Kendziorski CM, Zhang Y, Lan H, Attie AD. The efficiency of pooling mRNA in microarray experiments. Biostatistics 2003, 4:465-477. 10.1093/biostatistics/4.3.465, 12925512.
32. Peng X, Wood CL, Blalock EM, Chen KC, Landfield PW, Stromberg AJ. Statistical implications of pooling NA samples for microarray experiments. BMC Bioinformatics 2003, 4:26. 10.1186/1471-2105-4-26, 166151, 12823867.
33. Arthur MJ. Degradation of matrix proteins in liver fibrosis. Pathology research and practice 1994, 190:825-833.
34. Li X, Miyajima M, Mineki R, Taka H, Murayama K, Arai H. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Acta Neurochir (Wien) 2006, 148:859-864. 10.1007/s00701-006-0787-4, 16755327.
35. Janig E, Stumptner C, Fuchsbichler A, Denk H, Zatloukal K. Interaction of stress proteins with misfolded keratins. Eur J Cell Biol 2005, 84:329-39. 10.1016/j.ejcb.2004.12.018, 15819411.
36. Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA 1994, 91:7017-7021. 10.1073/pnas.91.15.7017, 44329, 8041738.
37. Hofmann B, Hecht HJ, Flohe L. Peroxideroxins. Biol Chem 2002, 383:347-364. 10.1515/BC.2002.040, 12033427.
38. Shimizu I. Recent Therapeutic Developments in Hepatic Fibrosis. Current Drug Targets Infectious Disorders 2001, 1:227-240. 10.2174/1568005014606053, 12455417.
39. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver International 2003, 23:63-69. 10.1034/j.1600-0676.2003.00811.x, 12640729.
40. Kim BJ, Hood BL, Aragon RA, Hardwick JP, Conrads TP, Veenstra TD, Song BJ. Increased oxidation and degradation of cytosolic proteins in alcohol-exposed mouse liver and hepatoma cells. Proteomics 2006, 6:1250-1260. 10.1002/pmic.200500447, 1368983, 16408314.
41. Meneses-Lorente G, Guest PC, Lawrence J, Muniappa N, Knowles MR, Skynner HA, Salim K, Cristea I, Mortishire-Smith R, Gaskell SJ, Watt A. A Proteomic Investigation of Drug-Induced Steatosis in Rat Liver. Chem Res Toxicol 2004, 17:605-612. 10.1021/tx034203n, 15144217.
42. Heijne WH, Slitt AL, van Bladeren PJ, Groten JP, Klaassen CD, Stierum RH, van Ommen B. Bromobenzene-Induced Hepatotoxicity at the Transcriptome Level. Toxicol Sci 2004, 79:411-422. 10.1093/toxsci/kfh128, 15056800.
43. Zhang W, Wang M, Xie HY, Zhou L, Meng XQ, Shi J, Zheng S. Role of Reactive Oxygen Species in Mediating Hepatic Ischemia-Reperfusion Injury and Its Therapeutic Applications in Liver Transplantation. Transplant Proc 2007, 39:1332-1337. 10.1016/j.transproceed.2006.11.021, 17580134.